Here are six key updates from Johnson & Johnson’s orthopedic business in 2025:
1. Johnson & Johnson is planning to separate its orthopedic business, which will operate as DePuy Synthes. Namal Nawana, former executive chair and founder of Sapphiros, will be worldwide president of DePuy Synthes. Johnson & Johnson is separating DePuy Synthes to shift its operational focus. Separation of DePuy Synthes is expected to be completed within 18 to 24 months.
2. Johnson & Johnson is partnering with Pacira BioSciences for osteoarthritis of the knee.
3. Johnson and Johnson launched its Kincise 2, an automated surgical impactor for hip and knee revisions.
4. The first cases using Velys Spine were completed at Mayo Clinic Rochester (Minn.) and Medical City Frisco (Texas).
5. Johnson & Johnson saw growth in its third-quarter orthopedic and total sales.
6. LifeNet Health and Johnson & Johnson MedTech launched the PliaFX Flo demineralized bone matrix.
